The anticipated decline in the biotech industry's ability to raise capital from public investors and an accompanying slump in biotech markets materialized in 2016, but all is not gloom and doom.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Senior, M. Billion-dollar deals end eras of Ariad and Actelion. Nat. Biotechnol. 35, 183–184 (2017).
Lawrence, S. Biotech's wellspring-a survey of the health of the private sector in 2016. Nat. Biotechnol. 35, 413–420 (2017).
Morrison, C. Fresh from the biotech pipeline—2016. Nat. Biotechnol. 35, 108–112 (2017).
Levin, J.M. et al. US immigration order strikes against biotech. Nat. Biotechnol. 35, 204–206 (2017).
Garber, K. Alnylam terminates revusiran program, stock plunges. Nat. Biotechnol. 34, 1213–1214 (2016).
Huggett, B. America's drug problem. Nat. Biotechnol. 34, 1231–1241 (2017).
Author information
Authors and Affiliations
Supplementary information
Supplementary Text and Figures
Supplementary Table 1 (XLS 212 kb)
Rights and permissions
About this article
Cite this article
Morrison, C., Lähteenmäki, R. Public biotech in 2016—the numbers. Nat Biotechnol 35, 623–629 (2017). https://doi.org/10.1038/nbt.3917
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3917
This article is cited by
-
Joint set-up of parameters in genetic algorithms and the artificial bee colony algorithm: an approach for cultivation process modelling
Soft Computing (2021)
-
Second-quarter biotech job picture
Nature Biotechnology (2017)
-
Epic $12 billion deal and FDA's approval raise CAR-T to new heights
Nature Biotechnology (2017)